Gross Profit Trends Compared: Eli Lilly and Company vs Merck & Co., Inc.

Eli Lilly vs. Merck: A Decade of Profit Growth

__timestampEli Lilly and CompanyMerck & Co., Inc.
Wednesday, January 1, 20141468310000025469000000
Thursday, January 1, 20151492150000024564000000
Friday, January 1, 20161556720000025916000000
Sunday, January 1, 20171680110000027347000000
Monday, January 1, 20181681160000028785000000
Tuesday, January 1, 20191759830000032728000000
Wednesday, January 1, 20201905650000027900000000
Friday, January 1, 20212100560000035078000000
Saturday, January 1, 20222191160000041872000000
Sunday, January 1, 20232704190000043989000000
Monday, January 1, 202436624400001
Loading chart...

Unleashing the power of data

Gross Profit Trends: Eli Lilly vs. Merck

In the competitive landscape of the pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Eli Lilly and Merck have shown significant growth in their gross profits. From 2014 to 2023, Eli Lilly's gross profit surged by approximately 84%, while Merck's increased by about 73%. This growth highlights the robust performance and strategic advancements of these industry giants.

Key Insights

  • Eli Lilly: Starting at $14.7 billion in 2014, Eli Lilly's gross profit reached $27 billion by 2023, reflecting a consistent upward trajectory.
  • Merck: With a starting point of $25.5 billion in 2014, Merck's gross profit climbed to $44 billion in 2023, showcasing its strong market presence.

These trends underscore the dynamic nature of the pharmaceutical sector, where innovation and strategic investments drive financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025